charles river laboratories international inc. - CRL

CRL

Close Chg Chg %
184.69 -0.73 -0.40%

Closed Market

183.96

-0.73 (0.40%)

Volume: 992.77K

Last Updated:

Dec 4, 2025, 3:59 PM EDT

Company Overview: charles river laboratories international inc. - CRL

CRL Key Data

Open

$183.51

Day Range

176.37 - 186.04

52 Week Range

91.86 - 202.57

Market Cap

$9.09B

Shares Outstanding

49.22M

Public Float

48.64M

Beta

1.64

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.55

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.09M

 

CRL Performance

1 Week
 
3.67%
 
1 Month
 
9.89%
 
3 Months
 
12.61%
 
1 Year
 
-3.72%
 
5 Years
 
-22.22%
 

CRL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About charles river laboratories international inc. - CRL

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

CRL At a Glance

Charles River Laboratories International, Inc.
251 Ballardvale Street
Wilmington, Massachusetts 01887
Phone 1-781-222-6000 Revenue 4.05B
Industry Miscellaneous Commercial Services Net Income 10.30M
Sector Commercial Services Employees 20,100
Fiscal Year-end 12 / 2025
View SEC Filings

CRL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 919.86
Price to Sales Ratio 2.338
Price to Book Ratio 2.71
Price to Cash Flow Ratio 12.89
Enterprise Value to EBITDA 13.023
Enterprise Value to Sales 2.986
Total Debt to Enterprise Value 0.23

CRL Efficiency

Revenue/Employee 201,491.99
Income Per Employee 512.289
Receivables Turnover 5.618
Total Asset Turnover 0.515

CRL Liquidity

Current Ratio 1.411
Quick Ratio 1.131
Cash Ratio 0.205

CRL Profitability

Gross Margin 31.345
Operating Margin 13.997
Pretax Margin 2.299
Net Margin 0.254
Return on Assets 0.131
Return on Equity 0.292
Return on Total Capital 0.165
Return on Invested Capital 0.16

CRL Capital Structure

Total Debt to Total Equity 80.343
Total Debt to Total Capital 44.55
Total Debt to Total Assets 36.941
Long-Term Debt to Equity 78.694
Long-Term Debt to Total Capital 43.636
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Charles River Laboratories International Inc. - CRL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
3.54B 3.98B 4.13B 4.05B
Sales Growth
+21.08% +12.31% +3.86% -1.92%
Cost of Goods Sold (COGS) incl D&A
2.33B 2.66B 2.74B 2.78B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
265.54M 303.87M 314.12M 361.74M
Depreciation
140.68M 157.29M 176.68M 223.27M
Amortization of Intangibles
124.86M 146.58M 137.44M 138.47M
COGS Growth
+18.91% +14.14% +2.92% +1.57%
Gross Income
1.21B 1.32B 1.39B 1.27B
Gross Income Growth
+25.48% +8.80% +5.75% -8.79%
Gross Profit Margin
+34.17% +33.10% +33.70% +31.35%
2021 2022 2023 2024 5-year trend
SG&A Expense
607.21M 663.49M 730.61M 702.60M
Research & Development
- - - -
-
Other SG&A
607.21M 663.49M 730.61M 702.60M
SGA Growth
+20.22% +9.27% +10.12% -3.83%
Other Operating Expense
- - - -
-
Unusual Expense
10.44M 25.20M 43.87M 352.43M
EBIT after Unusual Expense
591.99M 627.38M 617.26M 214.45M
Non Operating Income/Expense
(3.24M) 104.61M 100.73M 4.96M
Non-Operating Interest Income
652.00K 780.00K 5.20M 8.57M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
108.04M 109.00M 136.71M 126.29M
Interest Expense Growth
+40.12% +0.89% +25.42% -7.62%
Gross Interest Expense
108.04M 109.00M 136.71M 126.29M
Interest Capitalized
- - - -
-
Pretax Income
480.71M 622.99M 581.28M 93.11M
Pretax Income Growth
+7.51% +29.60% -6.69% -83.98%
Pretax Margin
+13.58% +15.67% +14.08% +2.30%
Income Tax
81.87M 130.38M 100.91M 67.82M
Income Tax - Current - Domestic
41.98M 94.84M 66.91M 48.52M
Income Tax - Current - Foreign
60.20M 68.64M 85.36M 86.49M
Income Tax - Deferred - Domestic
(34.20M) (31.97M) (52.13M) (60.27M)
Income Tax - Deferred - Foreign
13.89M (1.13M) 779.00K (6.92M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
398.84M 492.61M 480.37M 25.29M
Minority Interest Expense
7.86M 6.38M 5.75M 14.99M
Net Income
390.98M 486.23M 474.62M 10.30M
Net Income Growth
+7.32% +24.36% -2.39% -97.83%
Net Margin Growth
+11.04% +12.23% +11.49% +0.25%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
390.98M 486.23M 474.62M 10.30M
Preferred Dividends
- - - -
-
Net Income Available to Common
390.98M 486.23M 474.62M 10.30M
EPS (Basic)
7.7741 9.5691 9.2651 0.2004
EPS (Basic) Growth
+5.74% +23.09% -3.18% -97.84%
Basic Shares Outstanding
50.29M 50.81M 51.23M 51.38M
EPS (Diluted)
7.603 9.4779 9.2248 0.1994
EPS (Diluted) Growth
+5.63% +24.66% -2.67% -97.84%
Diluted Shares Outstanding
51.42M 51.30M 51.45M 51.63M
EBITDA
867.97M 956.46M 975.26M 928.62M
EBITDA Growth
+25.09% +10.19% +1.97% -4.78%
EBITDA Margin
+24.52% +24.06% +23.62% +22.93%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 191.357
Number of Ratings 19 Current Quarters Estimate 2.345
FY Report Date 12 / 2025 Current Year's Estimate 10.241
Last Quarter’s Earnings 2.43 Median PE on CY Estimate N/A
Year Ago Earnings 10.32 Next Fiscal Year Estimate 10.979
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 12 16 16
Mean Estimate 2.34 2.56 10.24 10.98
High Estimates 2.44 2.78 10.34 12.36
Low Estimate 2.25 2.37 10.15 10.35
Coefficient of Variance 2.08 4.98 0.51 4.57

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 6
OVERWEIGHT 2 2 1
HOLD 9 9 12
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Charles River Laboratories International Inc. - CRL

Date Name Shares Transaction Value
Feb 27, 2025 Birgit Girshick Corporate Executive VP & COO 54,628 Bona fide gift 0.00
Feb 24, 2025 James C. Foster Chairman, President and CEO; Director 183,639 Open market or private purchase of non-derivative security Non-derivative transaction at $165.01 per share 30,302,271.39
Feb 24, 2025 Joseph W. LaPlume EVP, Corp Strategy & Develop 20,013 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $162.5 per share 3,252,112.50

Charles River Laboratories International Inc. in the News